BioSpace News Archive

Amberstone Biosciences, an emerging biotherapeutics company with unique expertise in conditionally active immunotherapeutics, announced the completion of a $12 million Series A financing round.

Cardinal Health (NYSE: CAH) plans to release second-quarter financial results for its fiscal year 2022 on February 3 prior to the opening of trading on the New York Stock Exchange.

Seasoned Drug Developer Brings More Than Twenty Years of Medical Leadership and Clinical Oncology Experience.

Applied Therapeutics, Inc. today provided a regulatory update on the AT-007 Galactosemia program.

Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 , at 4:30 p.m. EST.

Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), and Oncoheroes Biosciences, Inc. (“Oncoheroes”), today announced that they have entered into licensing agreements under which Oncoheroes will acquire exclusive, global development rights to Allarity’s therapeutic candidates dovitinib, a pan-targeted kinase inhibitor (pan-TKI), and stenoparib.

Intra-Cellular Therapies, Inc. announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 7:30 am ET.

The industry analysis report is considered a valuable source of information about the global Transdermal Skin Patch industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.

MaaT Pharma announced that its CEO and co-founder, Hervé Affagard will present the company at the upcoming H.C. Wainwright Bioconnect Virtual Conference held January 10-13, 2022.

ERYTECH Pharma announced their participation in upcoming investor conferences and invites investors to participate in one-on-one meetings: